Getting your player ready...
INDIANAPOLIS — Eli Lilly and Co. has stopped developing a potential Alzheimer’s-disease treatment at a time when the drugmaker is searching wide and far for new drugs to fill a large revenue hole that will form starting next year.
The Indianapolis company said Tuesday preliminary results from late-stage studies of semagacestat showed it did not slow the progression of Alzheimer’s, and patients taking the drug fared worse than those on a placebo.
